Suppr超能文献

韦多利珠单抗诱导的急性间质性肾炎,韦多利珠单抗再次使用时类固醇预防失败。

Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge.

机构信息

Department of General Internal Medicine, Mater Hospital Brisbane, Brisbane, Queensland, Australia

Department of Nephrology, Mater Hospital Brisbane, Brisbane, Queensland, Australia.

出版信息

BMJ Case Rep. 2023 Sep 12;16(9):e254715. doi: 10.1136/bcr-2023-254715.

Abstract

Acute interstitial nephritis (AIN) is a common cause of acute kidney injury and renal failure. It is typically drug induced but can also be idiopathic or secondary to chronic infective or inflammatory conditions. Recent case reports suggest vedolizumab can be a causative agent for AIN. We report the case of a young man who presented with renal failure, fevers and constitutional symptoms. He had a complex history of refractory ulcerative colitis, prior colectomy and ileo-pouch-anal anastomosis with recurrent pouchitis. He had been receiving regular vedolizumab infusions for 6 months by the time of his presentation. A renal biopsy 4 months into his follow-up demonstrated AIN. Steroid prophylaxis with vedolizumab was trialled but ultimately failed, with worsening AIN and incomplete renal function recovery. To our knowledge, this is the first case of vedolizumab-induced AIN demonstrating a failure of steroid prophylaxis to prevent recurrence of AIN following vedolizumab rechallenge.

摘要

急性间质性肾炎(AIN)是急性肾损伤和肾衰竭的常见原因。它通常是由药物引起的,但也可能是特发性的,或继发于慢性感染或炎症性疾病。最近的病例报告表明,vedolizumab 可能是 AIN 的致病因素。我们报告了一例年轻男性,他因肾衰竭、发热和全身症状就诊。他有溃疡性结肠炎、先前的结肠切除术和回肠-袋-肛门吻合术以及反复 pouchitis 的复杂病史。在就诊时,他已经接受了 6 个月的常规 vedolizumab 输注。他随访 4 个月时的肾活检显示 AIN。vedolizumab 预防性使用类固醇进行了尝试,但最终失败,AIN 恶化,肾功能不完全恢复。据我们所知,这是首例 vedolizumab 诱导的 AIN 病例,表明在 vedolizumab 再挑战后,类固醇预防未能预防 AIN 的复发。

相似文献

2
Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review.
Scand J Gastroenterol. 2024 Jul;59(7):821-829. doi: 10.1080/00365521.2024.2345383. Epub 2024 Apr 29.
3
5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review.
Eur J Med Res. 2022 Apr 29;27(1):61. doi: 10.1186/s40001-022-00687-y.
6
7
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis.
Therap Adv Gastroenterol. 2024 Jul 30;17:17562848241258372. doi: 10.1177/17562848241258372. eCollection 2024.
9
A systematic review of vedolizumab in treating pediatric ulcerative colitis: efficacy and safety insights.
Therap Adv Gastroenterol. 2025 Jul 23;18:17562848251356063. doi: 10.1177/17562848251356063. eCollection 2025.
10

本文引用的文献

1
Renal and Urological Disorders Associated With Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2023 Aug 1;29(8):1306-1316. doi: 10.1093/ibd/izac140.
2
Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis.
ACG Case Rep J. 2022 Jun 24;9(6):e00788. doi: 10.14309/crj.0000000000000788. eCollection 2022 Jun.
3
Acute interstitial nephritis secondary to vedolizumab.
BMJ Case Rep. 2021 Nov 19;14(11):e243568. doi: 10.1136/bcr-2021-243568.
4
Ulcerative colitis: an update.
Clin Med (Lond). 2021 Mar;21(2):135-139. doi: 10.7861/clinmed.2021-0080.
5
Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report.
Am J Kidney Dis. 2018 Jan;71(1):142-145. doi: 10.1053/j.ajkd.2017.08.008. Epub 2017 Nov 20.
6
Interstitial nephritis associated with ulcerative colitis in monozygotic twins.
BMJ Case Rep. 2017 Feb 9;2017:bcr2016218346. doi: 10.1136/bcr-2016-218346.
7
Vedolizumab.
Aust Prescr. 2015 Dec;38(6):224-5. doi: 10.18773/austprescr.2015.081. Epub 2015 Oct 14.
9
Acute interstitial nephritis - a reappraisal and update.
Clin Nephrol. 2014 Sep;82(3):149-62. doi: 10.5414/cn108386.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验